若生智能
Drug Database
CO

COVID-19 vaccine (ZF2001 / Zifivax / ZF 2001)

✓ Approved

Anhui Zhifei Longcom Biopharma · 重组蛋白 · 重组蛋白

什么是 COVID-19 vaccine？

COVID-19 vaccine 是一种重组蛋白，由Anhui Zhifei Longcom Biopharma研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名ZF2001, Zifivax, ZF 2001
公司Anhui Zhifei Longcom Biopharma
药物类别重组蛋白, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Anhui Zhifei Longcom Biopharma

治疗适应症

COVID-19 vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsCOVID-19✓ Approved

相关研究文献

PubMedClinics in geriatric medicine2026-08-04

Vaccines for the Prevention of COVID-19 in Older Adults.

Olagunju Olajide J OJ, Oyebanji Oladayo A OA, Mylonakis Eleftherios E, Canaday David H DH

Institutionalized and community-dwelling older adults have been greatly impacted by the COVID-19 pandemic with increased morbidity and mortality. The advent of vaccines and their widespread use in this population has brought about a dramatic turnaround in COVID-19 outcomes. The immunogenicity and effectiveness of the various vaccine options worldwide will be discussed. Optimizing vaccine usage will remain crucial to maximize protection due to reduced initial immunity, the emergence of variant strains, and the waning of immunity over time. There are also lessons learned specific to older populations for future pandemics of novel pathogens where there is minimal to no prior immunity.

PMID 42547171
阅读全文 →
PubMedClinics in geriatric medicine2026-08-04

Epidemiology and Clinical Presentation of COVID-19 in Older Adults.

Abul Yasin Y, Leeder Ciera C, Gravenstein Stefan S

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remains asymptomatic in 33% to 90% of older adults depending on their immune status from prior infection, vaccination, and circulating strain. Older adults symptomatic with SARS-CoV-2 often both present atypically, such as with a blunted fever response, and develop more severe disease. Early and late reports showed that older adults have increased severity of coronavirus disease 2019 (COVID-19) with higher case fatality rates and higher intensive care needs compared with younger adults. Infection and vaccine-induced antibody response and long-term effects of COVID-19 also differ in older adults.

PMID 42547170
阅读全文 →
PubMedAfrican journal of primary health care & family medicine2026-08-04

Implementation evaluation of the COVID-19 vaccination: Speed, equity and mortality trends.

Matthew Ilona I, Viljoen Michelle M, McCartney Jane J

The coronavirus disease (COVID-19) vaccination campaign in South Africa constituted the most significant public health intervention in recent history, occurring against the backdrop of a prevailing quadruple burden of disease. To evaluate the implementation of the COVID-19 vaccination campaign, focusing on rollout speed and geographic equity and to examine the temporal associations between vaccination coverage and mortality trends. All South African residents aged 12 years and older who were eligible for COVID-19 vaccination during the study period. A retrospective, ecological population-based time-series analysis to assess vaccination rollout trends and geographic equity, and to examine the association between vaccination coverage and excess mortality. The Logic Model and the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework were applied to interpret implementation performance. The vaccination campaign expanded rapidly in the early phases, but vaccination activity declined significantly over a three-year period (p  0.001). By February 2024, approximately 49.7% of the eligible population had received at least one dose, below the national target of 67%. Coverage was higher in metropolitan than in district municipalities (p  0.05). Statistically significant non-causal temporal associations were observed between vaccination coverage and excess mortality. Early vaccine coverage was achieved, but uptake was insufficient to meet national coverage targets. Geographic disparities suggest potential inequities in access, offering empirical insights to strengthen primary health care integration, equitable service delivery, and data-driven implementation strategies.Contribution: This study supports dual-framework implementation science for evaluating large-scale public health interventions to inform health system strengthening and emergency preparedness.

PMID 42549726
阅读全文 →
PubMedJCO oncology advances2026-08-04

Evaluating Minority Participation in Radiation Oncology Clinical Trials and the Impact of COVID-19 on Enrollment in a Large Integrated Academic Satellite Network.

Echere Jovita J, Afolayan Oladipo K OK, Tate Molly M, Hubbard Qatalina Q et al.

Social distancing and health care rationing during the COVID-19 pandemic exacerbated cancer disparities. It is important to understand the impact of ethnic representation in clinical trials. We investigated how COVID-19 disease influenced racial/ethnic representation in radiation oncology (RO) trials in a large integrated academic satellite, hypothesizing that the pandemic significantly affected minority participation. We conducted an institutional review board-approved retrospective analysis of patients 18 years and older who enrolled in RO trials from March 2018 to August 2024 in a five-campus integrated academic satellite. Chi-square testing was used to compare variables across the COVID-19 periods. Statistical significance was considered for P values <.05, and statistical trends were considered for P values of .05-.1. A total of 1,702 patients were enrolled in RO trials: 531 (31.2%) pre-COVID-19, 843 (49.5%) during COVID-19, and 328 (19.3%) post-COVID-19. Racial/ethnic makeup was 79% White and 21% non-White. There was an increase in minority participation during COVID-19 (147 [17.5%]) compared with pre-COVID-19 (71 [12.5%]) and post-COVID-19 (46 [14.0%]) although this increase was not statistically significant (P = .06). The average distance from participants' homes to the treatment centers was significantly lower during COVID-19 (122 miles) compared with pre-COVID-19 (174 miles) and post-COVID-19 (187 miles; P < .01). Despite abundant literature suggesting the exacerbation of racial disparities in trials during COVID-19, we observed an increase in minority representation. Travel restrictions and regionally focused recruitment might have played a role. Future research should explore strategies focused on expanding outreach initiatives and integrating telehealth and patient education to enhance participation. By prioritizing equitable access to trials, we can improve cancer care and enhance the distribution of benefits and risks and the generalizability of research.

PMID 42549174
阅读全文 →
PubMedBrain sciences2026-08-04

RETRACTED: Frolli et al. The Impact of COVID-19 on Cognitive Development and Executive Functioning in Adolescents: A First Exploratory Investigation. Brain Sci. 2021, 11, 1222.

Frolli Alessandro A, Ricci Maria Carla MC, Di Carmine Francesca F, Lombardi Agnese A et al.

The journal retracts the article titled "The Impact of COVID-19 on Cognitive Development and Executive Functioning in Adolescents: A First Exploratory Investigation" [...].

PMID 42550467
阅读全文 →
PubMedQatar medical journal2026-08-04

New-onset adrenal insufficiency in COVID-19 patients without preexisting adrenal disease: A systematic review.

Fatima Iman I, Saif Muneeb Ali MA, Messova Assylzhan M AM, Abdrahmanova Sagira T ST et al.

Coronavirus disease 2019 (COVID-19) is increasingly recognized as a multisystem disorder with potential endocrine sequelae. Emerging reports suggest that adrenal insufficiency (AI) may occur in patients with COVID-19 without preexisting adrenal disease, but the clinical spectrum and strength of evidence remain unclear. To systematically review the literature on new-onset AI associated with COVID-19 in patients without prior adrenal disorders, focusing on clinical presentation, diagnostic approaches, and underlying mechanisms. A systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to December 28, 2025. Eligible studies included observational studies, case reports, and case series reporting AI in COVID-19 patients without known adrenal disease. Risk of bias was assessed using the Newcastle-Ottawa Scale and Joanna Briggs Institute tools. Given the heterogeneity, a qualitative synthesis was conducted. Nine primary studies (two observational studies and seven case reports) were included. Four narrative reviews were used solely for contextual discussion. Cases involved adults and children and occurred during acute infection or the post-COVID period. Most reports described biochemically confirmed central AI, while fewer reported primary AI due to adrenal infarction, hemorrhage, or autoimmune adrenalitis. Some presentations based mainly on steroid responsiveness were interpreted as probable critical illness-related corticosteroid insufficiency. Diagnostic thresholds and the use of ACTH stimulation testing varied. Most patients improved with glucocorticoid replacement. New-onset AI has been reported in temporal association with COVID-19 and may represent an infrequently reported but clinically significant endocrine manifestation. Prospective studies with standardized hormonal assessment are needed to clarify incidence, mechanisms, and screening strategies. The review was registered with PROSPERO under registration number CRD420251275141.

PMID 42549148
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多COVID-19 vaccine